Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Growth Metrics

Indivior Pharmaceuticals (INDV) Other financing activities (2024 - 2026)

Indivior Pharmaceuticals has reported Other financing activities over the past 2 years, most recently at $5.0 million for Q1 2026.

For Q1 2026, Other financing activities changed N/A year-over-year to $5.0 million; the TTM value through Mar 2026 reached $5.0 million, changed N/A, while the annual FY2024 figure was $2.0 million, N/A changed from the prior year.
Other financing activities for Q1 2026 was $5.0 million at Indivior Pharmaceuticals, up from -$1.0 million in the prior quarter.
Over five years, Other financing activities peaked at $5.0 million in Q1 2026 and troughed at -$1.0 million in Q1 2024.